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Frequency and Spectrum of c-Ki-ras
Mutations in Human Sporadic Colon
Carcinoma, Carcinomas Arising in
Ulcerative Colitis, and Pancreatic
Adenocarcinoma
by Glenna C. Burmer,* Peter S. Rabinovitch,* and
Lawrence A. Loebt
Sporadic colon carcinomas, carcinomas arising in chronic ulcerative colitis, and pancreatic adenocar-
cinomas have been analyzed for the presence of c-Ki-ras mutations by a combination of histological
enrichment, cell sorting, polymerase chain reaction, and direct sequencing. Although 60%o (37/61) of spo-
radic colon carcinomas contained mutations in codon 12, only 1 of17 specimens ofdysplasia orcarcinoma
fromulcerative colitispatients contained c-Ki-ras mutations, despite ahighfrequencyofaneuploidtumors.
In contrast, a higher percentage (16/20 = 80%o) ofpancreatic adenocarcinomas contained mutations in c-
Ki-ras 2, despite a lower frequency of DNA aneuploidy in these neoplasms. Moreover, the spectrum of
mutations differed between sporadic colon carcinoma, where the predominant mutation was a G to A
transition, and pancreatic carcinomas, which predominantly contained G to C or T transversions. These
results suggest that the etiology of ras mutations is different in these three human neoplasms.
Introduction
Neoplastic progression is hypothesized to occur by a
series of sequential genetic and epigenetic alterations
within a clonal population of cells that culminate in a
phenotype characterized by loss ofproliferative control
(1,2). In the human gastrointestinal tract, genetic al-
terations such as mutational activation of ras proto-
oncogenes have been implicated in tumor progression.
Mutations in c-Ki-ras 2 have been reported in 40 to 60%
of sporadic colon carcinomas (3-7) and in 75 to 90% of
pancreatic carcinomas (8-11). Their occurrence in pre-
cursor lesions such as colonic adenomas suggests that
ras mutations may be an early, initiating event in some
human tumors.
In animal model systems, activation of ras oncogenes
by specific base pair mutations appears to be an impor-
tant mechanism during the experimental induction of
tumors by chemical carcinogens (12,13). Moreover, in
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many cases, the spectrum ofmutations produced within
rasoncogenesbyaparticulardirect-actingchemicalcar-
cinogen correlates with the proposed mechanism ofac-
tion by that class of carcinogen (14-21). In human tu-
mors, however, the role of specific carcinogens in the
activation of ras oncogenes has not been defined. Al-
though carcinogens have been implicated in the genesis
ofsporadic colon cancer (22), much less is known about
the role of specific carcinogens in the development of
pancreatic carcinoma. Clearly, studies using human tu-
mormodelsystemsareneededtoclarifytherelationship
betweencarcinogenicexposure andrasmutations inthe
development of human cancer.
We have undertaken a retrospective analysis of the
frequency and spectrum of ras mutations in sporadic
human colon carcinomas, carcinomas arisingin patients
withlong-standingulcerativecolitis, andpancreaticcar-
cinomas using a combination of histologic enrichment,
cell sorting, the polymerase-catalyzed chain reaction
(PCR), and direct sequencing. In contrast to sporadic
colon carcinomas, mutations in c-Ki-ras were infre-
quently observed in carcinomas or areas of high-grade
dysplasia in patients with chronic ulcerative colitis.
Moreover, differences in the frequency and spectrum
of mutations observed in sporadic colon carcinoma and
pancreatic carcinoma suggest that a different class ofBURMER ET AL.
carcinogens may be involved in the initiation of these
two tumors.
Methodology
Case Selection
Cases ofsporadic colon carcinoma were selected from
patients without a prior history of malignancy, inflam-
matory bowel disease, familial colorectal carcinoma, or
prior chemotherapy. Cases from patients with chronic
ulcerative colitis were chosen with the following crite-
ria: at least 10 years ofulcerative colitis with evidence
of dysplasia or cancer, the absence of small intestinal
disease, the absence of pathologic changes suggestive
of Crohn's disease, and colonic involvement extending
proximal to the rectosigmoid. Twenty paraffin-embed-
ded cases of pancreatic adenocarcinoma were analyzed
for flow cytometric alterations in DNA content; cases
exhibiting aneuploid subpopulations were sorted prior
to DNA extraction and gene amplification, and diploid
carcinomas were enriched histologically to ensure that
at least 75% of the section contained tumor cells prior
to DNA extraction.
Flow Cytometry, Cell Sorting, PCR, and
DNA Sequencing
The detailed methodologies for our histologic enrich-
ment procedure, flow cytometric and cell sorting tech-
niques, PCR, and DNA sequencing methods for the c-
Ki-ras 2 first exon have been previously described
(6,7,23).
Results
Sporadic Colon Carcinoma
Mutations in the c-Ki-ras proto-oncogene have been
demonstrated in 40 to 60% ofsporadic colon carcinomas
by a number of different techniques, including oligo-
nucleotide hybridization, RNAse A mismatch cleavage
analysis, and PCR followed by direct sequencing (3-7).
Mutations have also been found in adenomas adjacent
to regions ofcarcinoma and in adenomas not associated
with cancer, suggesting that these mutations may be
an early event in neoplastic progression (3-5,7).
We have analyzed 61 sporadic colon carcinomas for
flow cytometric abnormalities and c-Ki-ras mutations
(6,7). Forty-six (75% + 6%) contained aneuploid DNA
populations, and 37 (60 6%) contained mutations in
codon 12 of c-Ki-ras 2 (Table 1). Twenty-seven of the
46 (59% + 7%) aneuploid carcinomas and 10 of the 15
(67% + 12%) diploid carcinomas contained mutations
within codon 12, but this difference was not statistically
significant.
Twenty-eight carcinomas were sorted into aneuploid
and diploid subpopulations and analyzed for c-Ki-ras
mutations. Six cases (21% + 8%) exhibited mutations
only within the aneuploid population, 10 cases (36% +
9%) contained mutations within both aneuploid and dip-
loid subpopulations, and 12 (43% + 9%) cases did not
contain ras mutations in either sorted cell population.
In two cases, mutations were detected in regions of
histologically benign mucosa adjacent to carcinoma (7).
The predominant mutation observed was a G to A
transition at the first base pair site ofcodon 12 (32/37);
G to T transversions were observed less frequently (4/
37), and only one tumor with a G to C transversion was
observed. Although G to A and G to T transversions
have been previously reported to be the most frequent
mutations in colorectal carcinomas (28/30 = 93%) (4),
ourresults differ by the predominance offirst base pair
site mutations in these tumors.
Statistically significant correlations were not ob-
served between the patient's age, sex, stage ofdisease
and the presence ofc-Ki-ras mutations (7). Our results
demonstrate that ras mutations may precede the de-
velopment offlow cytometrically detectable alterations
in ploidy and even morphologically identifiable changes
that are usually associated with histologic progression
in the development of colorectal carcinomas.
Carcinomas and Dysplasia Arising
in Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disease
that predisposes patients to the development of colo-
rectal carcinoma. In contrast to sporadic colon carci-
noma, in which the development of aneuploidy corre-
lates spatially with the histopathologic location of the
adenoma or carcinoma, the regions ofDNA aneuploidy
in ulcerative colitis patients may cover large areas of
colonic mucosa and may involve areas without recog-
nizable dysplasia (24-28). Moreover, dysplasia within
Table 1. DNA content and Ki-ras codon 12 mutations in sporadic colon carcinoma and ulcerative
colitis-associated dysplasia and carcinoma.'
Percent with Ki-ras
Disease Number ofpatients Percent aneuploid codon 12 mutations
Sporadic colon carcinoma 61 75 (46/61) 61 (37/61)
Ulcerative colitis carcinoma
and dysplasia 17 88 (15/17) 6 (1/17)
aShown are the tumortype, the number ofpatients analyzed, the percentage and fraction ofaneuploid tumors as assessed byflowcytometry,
and the percentage and fraction of tumors containing mutations in codon 12 of c-Ki-ras as assessed by polymerase chain reaction and direct
sequencing ofthe first exon of c-Ki-ras 2.
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ulcerative colitis may produce no grossly recognizable
lesion, whereas the dysplastic epithelium in sporadic
colon carcinoma characteristically produces an exophy-
tic mass. These clinical and flow cytometric differences
suggest that alternative pathways for tumorigenesis
may be involved in these two diseases.
Twenty-eight samples of carcinoma and dysplasia
from seventeen patients with chronic ulcerative colitis
were analyzed for flow cytometric alterations and mu-
tations in c-Ki-ras 2 (Table 1) (23). Aneuploid cell pop-
ulations were identified in 15/17 (88% ± 8%) of the
patients, withinareasofhigh-gradedysplasia, indefinite
for dysplasia, and negative for dysplasia.
In contrast to our results with sporadic colon carci-
nomas, however, c-Ki-ras codon 12mutations wereonly
found in one case of ulcerative colitis-associated carci-
noma. The mutation (a G to T transversion at the first
base pair site of codon 12), which was present in the
aneuploid cell population ofa carcinoma, was absent in
the diploid carcinoma subpopulation, two adjacent re-
gions ofmucosawith high-grade dysplasia, and aregion
of nearby mucosa with low-grade dysplasia (23). The
differenceinfrequencyofc-Ki-rasmutationsinsporadic
colon tumors compared to carcinoma and high-grade
dysplasiainulcerative colitispatientsisstatistically sig-
nificant.
Although inflammatory cells may constitute a high
proportion oftotal cells in ulcerative colitis specimens,
it is unlikely that this would have prevented our detec-
tion ofmutated ras sequences. In the 88% ofcases con-
taining aneuploid populations, cell sorting allowed sep-
aration of aneuploid tumor cells from diploid stromal
and inflammatory cells. In the remaining diploid cases,
regions were selected for analysis that contained min-
imal inflammation and in which tumor cells composed
greater than 75% ofthe section as assessed microscop-
ically.
Despite our tumor cell enrichment procedure, it is
possible that c-Ki-ras mutations may be present in ul-
cerativecolitis-associated carcinomas anddysplasiasbe-
low the sensitivity of detection by direct sequencing.
In mixing experiments, we have been able to detect
mutations that were present in 20% ofthe cells within
the mixed sample (10% oftotal alleles, assuming the c-
Ki-ras gene in the tumor is heterozygous for the mu-
tation); we cannot reliably identify mutations that are
presentinlowerfrequency. Thus, ifmutations are pres-
entinulcerative colitis, the cellsthatcontainthemmust
be a minority population within the tumor, which is in
marked contrast to sporadic colon carcinomas, where
mutations are readily detected by PCR and direct se-
quencing. These results suggest that the ras mutations
may play significantly different roles in the genesis of
sporadic colon carcinoma and carcinoma and dysplasia
arising in ulcerative colitis.
Pancreatic Adenocarcinomas
A number ofinvestigators have demonstrated that a
high frequency (75-90%) of human pancreatic adeno-
carcinomas containmutationswithinthe c-Ki-rasproto-
oncogene (8-11). The role of ras mutations in the eti-
ology of pancreatic carcinoma is uncertain, since the
presence of mutations has not been found to correlate
with the extent of disease or the degree ofdifferentia-
tion ofthe tumor, and more than one type ofmutation
has been detected within individual carcinomas or only
within a small subset ofcells within a carcinoma. How-
ever, investigators have suggested that the spectrum
of mutations in these carcinomas differs from those in
colorectal carcinomas and may more closely resemble
the spectrum of mutations seen in human lung adeno-
carcinomas (29,30). This observation has led to the hy-
pothesis that carcinogens within cigarette smoke may
serve as risk factors in the etiology of both of these
diseases (29,30).
Fiftypancreaticadenocarcinomashavebeenanalyzed
for DNA content abnormalities by flow cytometry and
to date, 20 of these cases have been analyzed for ras
mutations by PCR and direct sequencing (Table 2). In
contrast to the high frequency of aneuploid sporadic
colon carcinomas and ulcerative colitis-associated car-
cinomas, only 31 ofthe 50 (62% ± 7%) ofthe pancreatic
carcinoma specimens contained aneuploid cells. More-
over, the percentage ofaneuploid cells within the pan-
creatic carcinoma specimens was often lower than in
aneuploid colon carcinomas, and only six tumors con-
tained greater than 50% aneuploid cells.
Despite the lower percentage ofaneuploid pancreatic
neoplasms, 16 of the 20 tumors analyzed (80% ± 9%)
containedmutationsincodon 12ofc-Ki-ras 2. Oftumors
withrasmutations, 11(69% ± 12%)containedaneuploid
cells, and 5 (31% ± 12%) were diploid neoplasms. Mu-
tations were not observed in codon 13 or within the
remaining codons ofthe first exon of c-Ki-ras 2. There
Table 2. DNA content and c-Ki-ras codon 12 sequence of
pancreatic adenocarcinomas.a
K-ras codon 12 Amino acid
Case DNA content sequence codon 12
P-i 2.37 GTT Val
P-2 2.2 GCT Ala
P-3 2.3 CGT Arg
PA 3.3 GTT Val
P-5 2.0 GTT Val
P-6 2.0 GGT Gly
P-7 2.0 GAT Asp
P-8 2.0 GGT Gly
P-9 2.2 GGT Gly
P-10 4.0 GTT Val
P-11 2.0 GGT Gly
P-12 3.0 TGT Cys
P-13 3.4 CGT Arg
P-14 2.0 CGT Arg
P-15 4.6 CGT Arg
P-16 2.0 CGT Arg
P-17 2.7 CGT Arg
P-18 2.5 CGT Arg
P-19 2.0 CGT Arg
P-20 3.9 TGT Cys
aShown are the case number ofthe pancreatic carcinoma, the DNA
content (2.0 = diploid), the sequence ofc-Ki-ras codon 12 within the
tumor, and the corresponding amino acid for the sequence.
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Table 3. Spectrum of c-Ki-ras codon 12 mutations in pancreatic adenocarcinomas.a
Percentage oftumors with mutation
AGT CGT TGT GAT GCT GTT
Number analyzed (ser) (arg) (cys) (asp) (ala) (val) Reference
28 0 4 36 32 1 28 (8)
12 0 17 0 67 0 17 (11)
49 0 31 0 37 2 31 (10)
16 0 50 13 6 6 25 This report
aShown are the number ofneoplasms containing c-Ki-ras mutations, the percentage ofthese tumors with the indicated codon 12 sequence,
and the published reference from which the data was obtained.
was no statistically significant correlation between the
age or sex ofthe patient, the degree ofdifferentiation,
or the stage ofthe tumor.
The aneuploid pancreatic carcinomas containing ras
mutations were further sorted into aneuploid and dip-
loid subpopulations prior to PCR and sequencing. The
same mutations were observed in the tumors before
sorting and in the aneuploid populations analyzed after
sorting.
In contrast to our results with sporadic colon carci-
noma, where the predominant mutation consisted of a
G to A transition at the first base pair site, a wider
spectrum of mutations was observed within our pan-
creatic carcinomas (Table 3). The predominant muta-
tions observed were G to C or G to T transversions.
Our results are in agreement with investigators who
suggestthatthespectrumofmutationsinsporadiccolon
carcinomas differs from that in pancreatic neoplasms;
however, we do not see the predominance of G to T
transversions that have been reported in lung carci-
nomas which harbor a c-Ki-ras codon 12 mutation
(29,30).
Conclusion
This preliminary survey ofthree different human tu-
mors indicates that even in adenocarcinomas ofthe gas-
trointestinal tract, there is diversity in both the fre-
quency and spectrum of c-Ki-ras codon 12 mutations.
Our data provide support for the suggestion that dif-
ferent carcinogens may be involved in producing ras
mutations in sporadic colon carcinoma and pancreatic
carcinoma and provide evidence for a different role for
c-Ki-ras mutations in the genesis of neoplasms associ-
ated with sporadic colon carcinoma and carcinomas as-
sociated with ulcerative colitis.
The finding ofG:C to A:T transitions as the predom-
inant alteration in colon cancer suggests the possibility
tht these mutations result from errors in DNA repli-
cation orrepairduringthe course oftumorprogression.
The finding of G to T transversions in pancreatic car-
cinomas could be indicative of a chemical alteration in
DNA resulting in the formation ofan apurinic site (31).
The heterogeneity found in the spectrum ofmutations
in pancreatic carcinomas reported from different labo-
ratories, however, underlines the need for studies with
a large series of tumors before generalizations can be
made regarding the role of any specific carcinogen in
the development ofa human tumor.
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